166 related articles for article (PubMed ID: 38576104)
1. Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients.
Shalmon D; Bar-Ilan E; Peled A; Geller S; Bar J; Schwartz N; Sprecher E; Pavlovsky M
Acta Derm Venereol; 2024 Apr; 104():adv26663. PubMed ID: 38576104
[TBL] [Abstract][Full Text] [Related]
2. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.
Harano Y; Mitamura Y; Jiang P; Fujita T; Babazono A
J Diabetes Investig; 2023 Jun; 14(6):756-766. PubMed ID: 36897510
[TBL] [Abstract][Full Text] [Related]
3. The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study.
Lambadiari V; Kountouri A; Kousathana F; Korakas E; Kokkalis G; Theotokoglou S; Palaiodimou L; Katsimbri P; Ikonomidis I; Theodoropoulos K; Papadavid E
BMC Endocr Disord; 2021 Feb; 21(1):23. PubMed ID: 33573656
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis.
Phan K; Charlton O; Smith SD
Australas J Dermatol; 2020 Feb; 61(1):e15-e21. PubMed ID: 31215644
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases.
Jha A; Misra A; Gupta R; Ghosh A; Tyagi K; Dutta K; Arora B; Durani S
Diabetes Metab Syndr; 2020; 14(3):213-216. PubMed ID: 32172176
[TBL] [Abstract][Full Text] [Related]
6. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
Kridin K; Bergman R
JAMA Dermatol; 2018 Oct; 154(10):1152-1158. PubMed ID: 30090931
[TBL] [Abstract][Full Text] [Related]
7. Gliptin-Induced Bullous Pemphigoid: Canadian Case Series of 10 Patients.
Armanious M; AbuHilal M
J Cutan Med Surg; 2021; 25(2):163-168. PubMed ID: 33176433
[TBL] [Abstract][Full Text] [Related]
8. Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.
Gaudin O; Seta V; Alexandre M; Bohelay G; Aucouturier F; Mignot-Grootenboer S; Ingen-Housz-Oro S; Bernardeschi C; Schneider P; Mellottee B; Caux F; Prost-Squarcioni C
Front Immunol; 2018; 9():1030. PubMed ID: 29881377
[TBL] [Abstract][Full Text] [Related]
9. Bullous pemphigoid induced by vildagliptin: a report of three cases.
Béné J; Jacobsoone A; Coupe P; Auffret M; Babai S; Hillaire-Buys D; Jean-Pastor MJ; Vonarx M; Vermersch A; Tronquoy AF; Gautier S
Fundam Clin Pharmacol; 2015 Feb; 29(1):112-4. PubMed ID: 24861252
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
Lee H; Chung HJ; Pawar A; Patorno E; Kim DH
JAMA Dermatol; 2020 Oct; 156(10):1107-1114. PubMed ID: 32697283
[TBL] [Abstract][Full Text] [Related]
11. Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.
Nätynki A; Leisti P; Tuusa J; Varpuluoma O; Huilaja L; Izumi K; Herukka SK; Ukkola O; Junttila J; Kokkonen N; Tasanen K
Front Immunol; 2022; 13():942131. PubMed ID: 35958564
[TBL] [Abstract][Full Text] [Related]
12. Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population.
Plaquevent M; Tétart F; Fardet L; Ingen-Housz-Oro S; Valeyrie-Allanore L; Bernard P; Hebert V; Roussel A; Avenel-Audran M; Chaby G; D'Incan M; Ferrier-Le-Bouedec MC; Duvert-Lehembre S; Picard-Dahan C; Jeudy G; Collet E; Labeille B; Morice C; Richard MA; Bourgault-Villada I; Litrowski N; Bara C; Mahe E; Prost-Squarcioni C; Alexandre M; Quereux G; Bernier C; Soria A; Thomas-Beaulieu D; Pauwels C; Dereure O; Benichou J; Joly P; ;
J Invest Dermatol; 2019 Apr; 139(4):835-841. PubMed ID: 30543900
[TBL] [Abstract][Full Text] [Related]
13. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases.
Yoshiji S; Murakami T; Harashima SI; Ko R; Kashima R; Yabe D; Ogura M; Doi K; Inagaki N
J Diabetes Investig; 2018 Mar; 9(2):445-447. PubMed ID: 28520234
[TBL] [Abstract][Full Text] [Related]
14. Gliptin-induced bullous pemphigoid.
Ganeva M; Gancheva T; Manuelyan K; Hristakieva E
Int J Clin Pharmacol Ther; 2024 Feb; 62(2):89-95. PubMed ID: 38032147
[TBL] [Abstract][Full Text] [Related]
15. Association Between Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Cohort Study.
Magdaleno-Tapial J; Valenzuela-Oñate C; Esteban Hurtado Á; Ortiz-Salvador JM; Subiabre-Ferrer D; Ferrer-Guillén B; Giacaman-von der Weth M; García-Legaz Martínez M; Martínez-Domenech Á; Hernández-Bel P; Esteve-Martínez A; Pérez-Pastor G; Zaragoza-Ninet V; García-Rabasco A; Martínez-Aparicio A; Sánchez-Carazo JL; Pérez-Ferriols A; Alegre-de Miquel V
Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):249-253. PubMed ID: 31864538
[TBL] [Abstract][Full Text] [Related]
16. Bullous pemphigoid associated with the use of dipeptidil peptidase-4 inhibitors: analysis from studies based on pharmacovigilance databases.
Molina-Guarneros JA; Sainz-Gil M; Sanz-Fadrique R; García P; Rodríguez-Jiménez P; Navarro-García E; Martin LH
Int J Clin Pharm; 2020 Apr; 42(2):713-720. PubMed ID: 32140915
[TBL] [Abstract][Full Text] [Related]
17. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database.
Reolid A; Muñoz-Aceituno E; Rodríguez-Jiménez P; González-Rojano E; Llamas-Velasco M; Fraga J; Daudén E
Int J Dermatol; 2020 Feb; 59(2):197-206. PubMed ID: 31605541
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
Tasanen K; Varpuluoma O; Nishie W
Front Immunol; 2019; 10():1238. PubMed ID: 31275298
[TBL] [Abstract][Full Text] [Related]
19. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland.
Benzaquen M; Borradori L; Berbis P; Cazzaniga S; Valero R; Richard MA; Feldmeyer L
J Am Acad Dermatol; 2018 Jun; 78(6):1090-1096. PubMed ID: 29274348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
